Skip to main content
Clinical Trials/IRCT20240115060698N1
IRCT20240115060698N1
Recruiting
Phase 3

The assessment of probiotics' effects on gastrointestinal inflammation and symptoms in patients with scleroderma

Mashhad University of Medical Sciences0 sites44 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Scleroderma.
Sponsor
Mashhad University of Medical Sciences
Enrollment
44
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of scleroderma based on ACR\-Eular criteria
  • Patients aged 20 to 65 years
  • Scleroderma patients with malabsorption symptoms such as bloating, bowel dysfunction, cyclic constipation and diarrhea, heartburn
  • If taking corticosteroids, they have not changed the dose of corticosteroids in the past month.

Exclusion Criteria

  • Breastfeeding
  • Active infection
  • New organ involvement
  • Irritable bowel disease
  • Inflammatory bowel disease (IBD) and ulcerative colitis (UC)
  • Antibiotic intake in past 2 weeks
  • Probiotic intake in past 4 weeks
  • Endoxan in past 4 weeks
  • Rituximab in past 4 weeks
  • Biologic drugs in past 4 weeks

Outcomes

Primary Outcomes

Not specified

Similar Trials